How much is Eidos Therapeutics worth in 2026?

Eidos Therapeutics has a current valuation of N/A based on their Early Stage VC (Series B) round and secondary market data.

How much funding has Eidos Therapeutics raised?

Eidos Therapeutics has raised N/A in total funding across 1 funding rounds.

Eidos Therapeutics

Drug Discovery

Eidos Therapeutics valuation and funding history | Last updated: April 5, 2018 | 1 funding rounds

Current Valuation

N/A

As of April 5, 2018

Total Funding Raised

N/A

Across 1 round

Last Round

Early Stage VC (Series B)

$64.0M

Last Funding

Apr 2018

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
April 5, 2018	Early Stage VC (Series B)	$64.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Eidos Therapeutics is currently valued at N/A as of April 5, 2018.

Track Eidos Therapeutics Valuation Updates

Get notified when Eidos Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Eidos Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Eidos Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Eidos Therapeutics Worth in 2026?

Eidos Therapeutics is a leading private company in the Drug Discovery sector. Track Eidos Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Eidos Therapeutics Valuation is Determined

Private company valuations like Eidos Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.